News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1โ€“36
Matches
79
Sources here
2
Companies here
1
Search results Stored financial headlines

Active search

79 matching headlines

Ticker or company: TECNMain companies and provider mentions
Clear
Latest

finance.yahoo.com Analyst action

Tecan Group Stock Sees Modest Fair Value Lift After Analyst Target Increases

Tecan Group is back in focus after analysts lifted their fair value estimate from CHF 184.10 to CHF 195.73, reflecting updated price targets across recent research. Several firms have adjusted targets between CHF 151 and CHF 240, with some raising price goals without changing ratings. This helps explain the higher fair value used in current models. As you โ€ฆ

Main company ๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Read at finance.yahoo.com
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
Just inNext headlines
GlobeNewswire Analyst action Main company ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Tecan to participate in upcoming Investor Conference

Tecan Group AG Mรคnnedorf, Switzerland, September 10, 2026 โ€“ The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will participate in the following investor conference next week: 24th Annual Morgan Stanley Healthcare Conference, New York, USA Date: September 14, 2026 Time: 2:35pm โ€ฆ

TECN main company
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector?

The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune and neurological disorders. The suspension, effective August 24, followed three patient deaths caused by severe, โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Regulatory and legal Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall

Novartis AG NVS announced that the late-stage HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 (DM1) failed to meet the primary endpoint. Del-desiran is an investigational antibody oligonucleotide conjugate (AOC) designed to target the underlying cause of DM1. The global โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

HighCo: Half-Year 2026 Results

HIGHCO Aix-en-Provence, 09 September 2026 (6:00 p.m.) HIGHCO: GOOD PERFORMANCE IN H1 2026 (ADJUSTED HEADLINE PBIT UP 25% TO โ‚ฌ6.32 M AND ADJUSTED ATTRIBUTABLE NET INCOME UP 29.5% TO โ‚ฌ5 M); 2026 GUIDANCE REVISED Increase in business activity in H1 2026 driven by France โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?

Bristol Myers Squibb BMY announced positive phase II results from the registrational QUINTESSENTIAL study evaluating arlocabtagene autoleucel (arlo-cel; BMS-986393) in heavily pretreated patients with relapsed and refractory multiple myeloma. Arlo-cel is a potential first-in-class autologous G protein-coupled receptor class C group 5 member D โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Analyst action Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says

Dyne Therapeutics (DYN) investment thesis remains intact despite a setback for Novartis (NVS) in a p PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Analyst action Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls

Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Company News for Sep 9, 2026

QUALCOMM Incorporated (QCOM) shares rose 3.2% on optimism over its new data center partnership with Amazon Web Services and its AI growth prospects. Roivant Sciences Ltd. (ROIV) shares surged18.8% after positive Phase 2 results for its pulmonary hypertension drug candidate mosliciguat. Bloom Energy Corporation โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Guidance Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC

Company Logo Opportunities center on earlier genetic diagnosis, targeted FGFR3 therapies, long-acting CNP analogs and oral inhibitors. Developers can improve access, affordability, adherence and lifelong complication management across the US, Europe and Japan. Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Achondroplasia - Market โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Market update Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Giovanni Caforio Appointed Operating Advisor to CD&R Funds

LONDON, Sept. 9, 2026 /PRNewswire/ -- CD&R (or the "Firm") today announced the appointment of Giovanni Caforio as an Operating Advisor to CD&R funds. The Firm believes his 35-year career in the international biopharmaceutical industry will be invaluable as he supports CD&R funds in โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Analyst action Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Sector Update: Healthcare Stocks Fall Late Afternoon

Healthcare stocks declined late Tuesday afternoon with the NYSE Healthcare Index falling 2.5% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Market update Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

How Novartis' Double-Stacked Failures Reverberated Through Biopharma

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop. Continue Reading

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Analyst action Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says

Amgen's (AMGN) experimental heart drug olpasiran may still show a meaningful reduction in major card PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Deals and strategy Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis Crashes 13.5% After $12 Billion Deal's Lead Drug Fails

This article first appeared on GuruFocus. Novartis (NYSE:NVS), the Swiss pharmaceutical giant, absorbed a brutal setback Tuesday after del-desiran missed the primary endpoint in a pivotal myotonic-dystrophy trial. The stock plunged 10.1% to $138.51, erasing approximately CHF24 billion from the company's market value, according โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Analyst action Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis Trial Failure Sparks Biopharma Options Frenzy

Biopharma stocks are dominating the unusual options volume list today, after a high-profile clinical trial failure from Novartis AG (NYSE:NVS) sent shockwaves through the sector. NVS is headed for its worst single-session performance on record, while Amgen Inc (NASDAQ:AMGN) and NewAmsterdam Pharma Company NV โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Analyst action Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

European Stocks Close Mixed in Tuesday Trading; Oil Prices Surge As Middle East Fighting Worsens

The European stock markets closed mixed in Tuesday trading amid rising hostilities in the Middle Eas PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Deals and strategy Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis Stock Tanks Following Third Major Pipeline Setback

Following two trial misses and a third clinical setback, analysts fear Novartis may miss its 2030 growth targets without further acquisitions. Continue Reading

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Analyst action Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts

Investing.com -- BMO Capital Markets downgraded Amgen and BioNTech to Market Perform from Outperform on Tuesday, citing limited near-term upside and more balanced risk-reward for biopharma companies. BMO analyst Evan Seigerman cut Amgen's rating while maintaining a price target of $450. Seigerman said commercial โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Market update Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

Monte Rosa Therapeutics, Inc. Phase 2 study to be conducted in participants with Sjรถgren's disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Regulatory and legal Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-desiran showed evidence of clinical activity in secondary endpoints โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Balance sheet Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Amgen's 7,297-Patient Heart Bet Just Inherited a Higher Bar

This article first appeared on GuruFocus. Amgen (NASDAQ:AMGN), the biotechnology heavyweight behind Repatha and experimental olpasiran, inherited a tougher burden of proof as its shares stood at $437.23. Novartis's pelacarsen successfully lowered lipoprotein(a), or Lp(a), but failed to cut major cardiovascular events in a โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis (NVS) Has a Potential $3 Billion MS Opportunity โ€” But Investors Face Key Risks

Novartis AG (NYSE:NVS) could be staring at a $3 billion annual peak-sales opportunity in multiple sclerosis (MS) if its drug remibrutinib successfully advances through the regulatory process and gains meaningful market share. Bank of America estimates that remibrutinib could generate about $3 billion in โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis Falls 1.9% as Pelacarsen Failure Erases CHF4.9 Billion

This article first appeared on GuruFocus. Novartis (NYSE:NVS), the Swiss pharmaceutical giant, traded at $159.99 Monday after pelacarsen flopped in a pivotal Phase 3 cardiovascular trial. Reuters estimated that roughly CHF4.9 billion evaporated from the company's market value, while its Zurich-listed shares fell 1.9%. โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Regulatory and legal Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down

Novartis NVS announced that the late-stage study on investigational candidate, pelacarsen, failed. Pelacarsen is an investigational antisense oligonucleotide (ASO) designed to potently inhibit lipoprotein (a), Lp(a), production at its source. Novartis secured global rights from Ionis Pharmaceuticals IONS to develop, manufacture and commercialize pelacarsen โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Capital return Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Melexis: update on the share buy-back program

Melexis N.V. Press release - Regulated Information Melexis: update on the share buy-back program Ieper, Belgium โ€“ 7 September 2026, 17.45 hrs CET Melexis reports the purchase of 9,920 Melexis shares on Euronext Brussels in the period from 31 August 2026 to 4 September โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Regulatory and legal Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal

Shares of Amgen AMGN were down 5% in after-hours trading on Friday after Novartis NVS announced that the phase III Lp(a)HORIZON study evaluating the latter's investigational drug pelacarsen in patients with elevated lipoprotein (a) Lp(a) and established cardiovascular disease (CVD) did not meet its โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Market update Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis Just Lost a Potential $6 Billion Drug Opportunity

This article first appeared on GuruFocus. Novartis AG (NVS, Financials) has received a sobering reminder of how quickly billions of dollars in prospective medicine sales can disappear. Its experimental cholesterol drug pelacarsen failed in a high-profile late-stage study. Is NVS fairly valued? Test your โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Regulatory and legal Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah

AstraZeneca AZN announced that the FDA has approved Etcamah (camizestrant) in combination with a medicine belonging to the class of cyclin-dependent kinase (CDK) 4/6 inhibitors for the treatment of certain patients with advanced breast cancer. The approval was granted under the accelerated pathway. The โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?

In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year. Continue Reading

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Royalty Pharma announces update on Novartisโ€™ Phase 3 topline results for pelacarsen

Royalty Pharma plc NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis' Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis, Ionis Tumble On Surprise Flop For Heart Drug

Novartis said late Friday its Ionis-partnered Lp(a) blocker failed in testing. The results sent Novartis and Ionis stocks tumbling. Continue Reading

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR Basel, September 4, 2026 โ€“ Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events, โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Is Novartis (SWX:NOVN) Overvalued After Its Phase III Remibrutinib Win?

Novartis (SWX:NOVN) is back in focus after reporting positive Phase III REMODEL-1 and REMODEL-2 results for its oral BTK inhibitor remibrutinib in relapsing multiple sclerosis, supporting planned global regulatory filings. At a share price of CHF131.32, Novartis has seen building momentum, with a 7 โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Market update Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

Novartis (NVS)โ€™s Latest Basel Move Signals a Shift in Strategic Priorities

Novartis AG (NYSE:NVS) could cut around 130 jobs in Switzerland as it relocates laboratory activities and ends small-scale biologics production at its Kleinbasel site in Basel. The company plans to move laboratories supporting biological cell banks, analytical testing and technical development to its main โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026
finance.yahoo.com Earnings Provider-linked mention ๐Ÿ‡จ๐Ÿ‡ญ Switzerland

dorma+kaba Holding AG (DRMKY) (FY 2026) Earnings Call Highlights: Record Margins and Strategic ...

This article first appeared on GuruFocus. Net Sales: CHF2,792.4 million, with organic growth of 3%. Adjusted EBITDA Margin: Record 16.1%, an improvement of 60 basis points year-on-year. Adjusted EBITDA: Increased to CHF449 million. Organic Growth Drivers: Pricing of plus 2.6% and volume growth of โ€ฆ

TECN mentioned
Sharemaestro market context Trend signal active 52 weeks +58.9% ยท Next-week setup positive 62.1% TECN stored weekly price path from 10 Oct 2025 to 2 Oct 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context